Results 91 to 100 of about 24,853 (244)

Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era

Haematologica
The recent progress with ruxolitinib treatment might improve quality-of-life as well as overall survival in patients with primary myelofibrosis (PMF).
Yosuke Okada, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Kazuki Yoshimura, Masaharu Tamaki, Akari Matsuoka, Takuto Ishikawa, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Machiko Kusuda, Aki Tanihara, Shun-ichi Kimura, Shinichi Kako, Yoshinobu Kanda   +18 more
doaj   +1 more source

Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial

Leukemia and Lymphoma
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor momelotinib by anemia severity, we performed a ...
Vikas Gupta, Stephen T. Oh, Timothy Devos, Viviane Dubruille, J. Catalano, T. Somervaille, U. Platzbecker, Pilar Giraldo, Hiroshi Kosugi, Tomasz Sacha, J. Mayer, Á. Illés, Catherine E Ellis, Zhaohui Wang, Francisco Gonzalez Carreras, B. Strouse, R. Mesa   +16 more
semanticscholar   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

The JAK1/JAK2 inhibitor ruxolitinib inhibits mediator release from human basophils and mast cells

Frontiers in Immunology
Introduction The Janus kinase (JAK) family includes four cytoplasmic tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) constitutively bound to several cytokine receptors. JAKs phosphorylate downstream signal transducers and activators of transcription (STAT).
R. Poto, Leonardo Cristinziano, Gjada Criscuolo, Caterina Strisciuglio, Francesco Palestra, Gianluca Lagnese, Antonio di Salvatore, G. Marone, G. Spadaro, S. Loffredo, G. Varricchi   +10 more
semanticscholar   +1 more source

Janus kinase inhibitors after ruxolitinib failure in myelofibrosis: A systematic review and pooled analysis of phase 3 efficacy and integrated safety across clinical trials and real‐world evidence

British Journal of Haematology, EarlyView.
Summary Ruxolitinib remains first‐line standard of care for symptomatic myelofibrosis, but resistance/intolerance develops in most patients. Three Janus kinase inhibitors (JAKis) have entered the post‐ruxolitinib space via distinct pivotal trials. We systematically searched prospective trials evaluating JAKi in refractory adults with myelofibrosis ...
Andrea Duminuco, Patrick Harrington, Elena Torre, Hillary Catellani, Novella Pugliese, Matteo Pacilli, Annalisa Santisi, Arianna Sbriglione, Giuseppe A. Palumbo   +8 more
wiley   +1 more source

Ruxolitinib plus standard of care in severe hospitalized adults with severe fever with thrombocytopenia syndrome (SFTS): an exploratory, single-arm trial

BMC Medicine
Background Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious disease, and its morbidity and mortality are increasing. At present, there is no specific therapy available.
Sai-lan Wen, Nannan Xu, Lianhui Zhao, Lulu Yang, Hui Yang, Caiyun Chang, Shanshan Wang, Chunmei Qu, Li Song, Wenlu Zou, Yishan He, Gang Wang   +11 more
semanticscholar   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Haematologica, 2016
RESPONSE is an open-label phase 3 study evaluating the Janus kinase 1/Janus kinase 2 inhibitor ruxolitinib versus best available therapy for efficacy/safety in hydroxyurea-resistant or intolerant patients with polycythemia vera.
Srdan Verstovsek, Alessandro M. Vannucchi, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N. Harrison, Fabrizio Pane, Pierre Zachee, Keita Kirito, Carlos Besses, Masayuki Hino, Beatriz Moiraghi, Carole B. Miller, Mario Cazzola, Vittorio Rosti, Igor Blau, Ruben Mesa, Mark M. Jones, Huiling Zhen, Jingjin Li, Nathalie Francillard, Dany Habr, Jean-Jacques Kiladjian   +23 more
doaj   +1 more source

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, restores blood–brain barrier integrity in a human stem cell‐based model of ischaemic stroke

British Journal of Pharmacology, EarlyView.
Ischaemic stroke is characterised by acute cerebrovascular occlusion and blood–brain barrier (BBB) breakdown. Our results indicated that the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) ameliorated the loss of BBB integrity, changed the morphology of brain endothelial cells, increased the level of basement membrane and ...
Anikó Szecskó, Koppány Párdi, Zuhao Cui, Gergő Porkoláb, Zsófia Hoyk, Csilla Kovács, Janet F. Adegbite, Virág Fodor, Nárcisz M. Cser, László Dér, Krisztina Nagy, Csilla Sajben, Roland Tengölics, Mária A. Deli, Szilvia Veszelka   +14 more
wiley   +1 more source